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AbstrAct
Background The cardiometabolic effects of SRT2104, 
a novel SIRT1 activator, were investigated in people with 
type 2 diabetes mellitus (T2DM).
Methods Fifteen adults with T2DM underwent a 
randomised, double-blind, placebo-controlled cross-over 
trial and received 28 days of oral SRT2104 (2.0 g/day) 
or placebo. Forearm vasodilatation (measured during 
intrabrachial bradykinin, acetylcholine and sodium 
nitroprusside infusions) as well as markers of glycaemic 
control, lipid profile, plasma fibrinolytic factors, and 
markers of platelet-monocyte activation, were measured 
at baseline and at the end of each treatment period.
Results Lipid profile and platelet-monocyte 
activation were similar in both treatment arms 
(p>0.05 for all). Forearm vasodilatation was 
similar on exposure to acetylcholine and sodium 
nitroprusside (p>0.05, respectively). Bradykinin-induced 
vasodilatation was less during treatment with SRT2104 
versus placebo (7.753vs9.044, respectively, mean 
difference=−1.291,(95% CI −2.296 to −0.285, p=0.012)). 
Estimated net plasminogen activator inhibitor type 1 
antigen release was reduced in the SRT2104 arm versus 
placebo (mean difference=−38.89 ng/100 mL tissue/
min, (95% CI −75.47, to –2.305, p=0.038)). There were 
no differences in other plasma fibrinolytic factors (p>0.05 
for all). After 28 days, SRT2104 exposure was associated 
with weight reduction (−0.93 kg (95% CI −1.72 to −0.15), 
p=0.0236), and a rise in glycated haemoglobin (5 mmol/
mol or 0.48% (0.26 to 0.70), p=0.004)
Conclusions In people with T2DM, SRT2104 had 
inconsistent, predominantly neutral effects on endothelial 
and fibrinolytic function, and no discernible effect on lipids 
or platelet function. In contrast, weight loss was induced 
along with deterioration in glycaemic control, suggestive of 
potentially important metabolic effects.
Clinical trial registration NCT01031108; Results.
IntRoduCtIon
The effect of caloric restriction on energy 
metabolism has attracted intense interest 
over the past decade because it prolongs the 
life span in yeast, nematodes and flies. Caloric 
restriction also lowers the incidence of age-re-
lated disorders such as diabetes and cancer 
in mammals.1–5 These beneficial effects 
may be mediated by sirtuins, (‘SIR-2-ins’ or 
silent mating-type information regulation 
2). In yeast, the sirtuin gene regulates many 
cellular pathways including inflammation, 
apoptosis and mitochondrial biogenesis. The 
activity of sirtuins is dependent on nicotina-
mide adenine dinucleotide , thereby linking 
energy metabolism and caloric restriction to 
these important cellular pathways.6
The mammalian homologue of the sirtuins 
is SIRT1.7 In murine models, activation of 
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Key Questions
What is already known about this subject?
 ► Sirtuins are a group of proteins that regulate many 
important biological pathways. Specifically, SIRT1 
mediates the beneficial effects of caloric restriction 
on endothelial function and on glucose regulation 
in animal models. The cardiometabolic effects of 
SIRT1 activation in humans are unknown; it is this 
research question that underpins this randomised 
clinical trial.
What does this study add?
 ► It appears that short-term SIRT1 activation in 
humans is well tolerated, and has predominantly 
neutral effects on markers of endothelial function 
and platelet-monocyte function. However, it is 
associated with weight reduction and a rise in 
glycated haemoglobin.
How might this impact on clinical practice?
 ► The reduction in weight suggests that SIRT1 
activation indeed modulates important biological 
pathways related to energy metabolism. People 
with type 2 diabetes mellitus have a high 
prevalence of obesity, and this finding of weight 
loss merits closer investigation. The rise in glycated 
haemoglobin is not consistent with results from 
animal model studies. We speculate that the 
deterioration in glucose control may be a signal 
of inadequate reduction in insulin resistance in 
humans. Further studies are required to confirm 
this signal, which will impact on the feasibility of 
development of this novel class of drugs.
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SIRT1 has been implicated in the modulation of several 
cellular substrates including peroxisome proliferator-ac-
tivated γ cofactor 1-α, nuclear factor κ-B, foxhead box 
protein and uncoupling proteins.8–10 These pathways 
are implicated in skeletal muscle energy metabolism and 
adipocyte differentiation, and play a role in glucose 
regulation in skeletal muscle and pancreatic β cells, as 
well as modulating insulin sensitivity.11 Caloric restric-
tion also improves endothelial function in rodent and 
human studies through weight loss, improvement of 
nitric oxide production and reduction in reactive-ox-
ygen species.12–14 Inhibition of SIRT1 promotes athero-
genesis and upregulation of SIRT1 increases nitric oxide 
in rodent models.15–17 As a caloric restriction mimetic, 
SIRT1 activation therefore has the potential to improve 
cardiovascular health and mitigate the adverse effects of 
atherosclerotic disease and its risk factors.
Type 2 diabetes mellitus (T2DM) is a highly preva-
lent chronic condition, estimated to affect 4.4% of the 
worldwide population by 2030.18 It is associated with 
an increasing economic burden and in the USA total 
costs are estimated to be $245 billion.19 The major cause 
of mortality in patients with T2DM is cardiovascular 
disease. One of the putative mechanisms of the link 
between cardiovascular disorders and T2DM is endothe-
lial dysfunction.20 Thus, modulation of SIRT1 is a prom-
ising strategy for the treatment of both diabetes and its 
well documented association with cardiovascular disease.
To date, studies have primarily investigated the ex vivo 
effect of SIRT1 activation. We hypothesised that thera-
peutic SIRT1 activation would have beneficial effects on 
cardiometabolic health in people with diabetes. Specifi-
cally, we examined the effect of a novel SIRT1 activator, 
SRT2104, on vascular vasomotor and fibrinolytic func-
tion, platelet activation, lipid profile and markers of 
glycaemic control in people with T2DM.
MetHods
The study was approved by the research ethics committee, 
was given clinical trial authorisation by the Medicines and 
Healthcare products Regulatory Agency (MHRA), and 
carried out at the MHRA phase I accredited Wellcome 
Trust Clinical Research Facility at the Western General 
Hospital, UK. Written informed consent was obtained 
from each participant, and the study was carried out in 
accordance with the Declaration of Helsinki.
study participants
Fifteen individuals with T2DM were recruited from outpa-
tient clinics at the Royal Infirmary of Edinburgh. Inclu-
sion criteria included age between 18 years and 70 years, 
glycated haemoglobin (HbA1c)  <9.0% (75 mmol/mol) 
and resting blood pressure of <160/90 mm Hg. Exclu-
sion criteria included current smokers, the use of ACE 
inhibition therapy (as the potentiation of bradykinin 
and effects on endothelial function would confound the 
vascular studies), the presence of major comorbidities, 
chronic illness, renal or liver impairment, history of 
gastrointestinal diseases or surgeries influencing drug 
absorption, history of alcoholism, history of neoplastic 
disease within the last 5 years, a positive urinary test for 
recreational drugs, pregnancy, and participation in other 
clinical trials or blood donation within the last 3 months. 
Eligibility of participants including absence of relevant 
medical history was confirmed through a standardised 
form completed by the subject’s primary care physician 
after obtaining informed consent. Tests for pregnancy 
(serum human chorionic gonadotropin (HCG) concen-
trations at screening and urinary HCG concentrations at 
study visits) were conducted on all female participants of 
childbearing potential.
study design
This was a prospective, double-blind, randomised, place-
bo-controlled cross-over study. Subjects were randomised 
1:1 to receive 2.0 g daily of oral SRT2104 or matched 
placebo (Sirtris Pharmaceuticals) for a 28-day period, 
followed by cross-over to the alternate study arm for 
another 28 days, giving a total dosing duration of 56 days. 
A safety visit was conducted on day 70, with a follow-up 
by telephone on day 86. Assessment of drug safety, toler-
ability and efficacy on vascular function was carried out 
at baseline, and during and at the end of each treatment 
period (figure 1). The overall study design included 
otherwise healthy smokers in addition to people with 
T2DM, and volunteers were stratified by these two cate-
gories. This manuscript focuses on the T2DM group, 
with observations in the otherwise healthy smokers group 
described previously.21
Vascular studies
Vascular studies were undertaken before and at the end 
of each 28-day trial period. All studies were performed 
with the patient lying supine in a quiet temperature-con-
trolled (22°C to 25°C) room. Participants were fasted for 
10 hours, and avoided caffeine and alcohol for 24 hours, 
before the study. Venous cannulae (17G) were inserted 
into large subcutaneous veins in the antecubital fossae of 
both arms to facilitate periodic venous sampling. Supine 
heart rate and blood pressure were monitored at intervals 
throughout the study using a semiautomated, non-inva-
sive oscillometric sphygmomanometer (Omron 705 IT).
Forearm venous occlusion plethysmography
Forearm blood flow was measured in the infused and 
non-infused forearms using forearm venous occlusion 
plethysmography as described previously.22 Volunteers 
underwent brachial artery cannulation in the non-dom-
inant forearm with a 27 standard wire gauge steel 
needle. After a 20 min baseline infusion with 0.9% saline, 
incremental intra-arterial doses of bradykinin (Amer-
ican Peptide) at 100 pmol/min, 300 pmol/min and 
1000 pmol/min (an endothelium-dependent vasodilator 
that induces tissue plasminogen activator (t-PA) release), 
acetylcholine (Chem. Pharm Fabrik) at 5 µg/min, 10 µg/
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Figure 1 Study design: schematic representation of study design. PK, pharmacokinetic; SCR, screening.
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min and 20 µg/min (an endothelium-dependent vasodi-
lator that does not induce t-PA release) and sodium nitro-
prusside (Hospira) at 2 µg/min, 4 µg/min and 8 µg/min 
(an endothelium-independent vasodilator that does not 
induce t-PA release) were infused for 6 min at each dose, 
with a 30 min 0.9% saline washout infusion between drugs. 
The order of drugs was randomised between subjects but 
kept constant for each participant across the three visits.
Blood sampling
Paired venous blood samples were obtained from each 
forearm before and during the infusion of intra-arte-
rial bradykinin. Samples were collected into acidified 
buffered citrate (Stabilyte; Trinity Biotech) and citrate 
(BD Vacutainer; BD UK) for determination of t-PA and 
plasminogen activator inhibitor type 1 (PAI-1) concen-
trations, respectively. Samples were placed on ice before 
centrifuging at 2000 g for 30 min at 4°C. Platelet-free 
plasma was decanted and stored at −80°C before further 
analysis. Venous blood samples were collected into EDTA 
at the beginning and end of the vascular study to deter-
mine haematocrit.
Plasma t-PA antigen and activity (t-PA Combi Actibind 
t-PA ELISA kit; Technoclone, Vienna, Austria) and PAI-1 
antigen and activity (Elitest PAI-1 Antigen and Zymutest 
PAI-1 Activity; Hyphen Biomed) concentrations were 
determined by ELISAs.
Platelet and monocyte activation
Flow-cytometric measurements of platelet–monocyte 
aggregation and platelet surface expression of P-selectin 
and monocyte CD11b expression (Mac-1/CD11b) were 
performed at baseline and at the end of each treatment 
period as described previously.23–26 Briefly, peripheral 
venous blood was drawn from a large antecubital vein and 
anticoagulated with the direct thrombin inhibitor D-phe-
nylalanine-L-arginine chloromethyl ketone (Cambridge 
Biosciences) and immunolabelled within 5 min of phle-
botomy for subsequent flow cytometric analysis. Directly 
conjugated monoclonal antibodies were obtained from 
DakoCytomation and Serotec. Samples were stained with 
the following conjugated monoclonal antibodies: phyco-
erythrin (PE)–conjugated CD14, PE-conjugated CD62p, 
PE-conjugated CD11b, ﬂuorescein isothiocyanate 
(FITC)–conjugated 42a and FITC-conjugated CD14 and 
appropriate control isotypes. Once stained, samples were 
incubated for 20 min at room temperature before being 
fixed with Fluorescence-activated cell sorting (FACS) 
Lyse (Becton-Dickinson). All samples were analysed 
using a FACS Calibur flow cytometer using CellQuest Pro 
software (Becton-Dickinson). Venous blood was collected 
in citrate at baseline and after each dosing period to 
assess plasma-soluble CD40 ligand concentrations. Blood 
was centrifuged at 1500 g for 15 min at 4°C, and plasma 
was decanted and stored at −80°C for further analysis by 
ELISA (Bender Medsystems).
safety and pharmacokinetic analyses
Venous blood samples were collected biweekly to measure 
haematological and biochemical parameters including 
full blood count, coagulation profile, liver and renal func-
tion, creatine phosphokinase, lactate dehydrogenase, 
lipid profile and free fatty acids. Analyses were conducted 
by the regional clinical haematology and biochemistry 
reference laboratories using an automated haematology 
analyser (XE2100, Sysmex Corporation and ACL TOP, 
Instrumentation Laboratory), an automated chemistry 
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Table 1 Summary of treatment-emergent adverse events. 
Multiple adverse events for each subject are counted once 
within each unique category
System Adverse event
Number of subjects 
with events 
(percentage)
Placebo 
(n=14)
SRT2104 
(n=15)
Immune system Any event 1 (7%) 0
Seasonal allergy 1 (7%) 0
Vascular Any event 0 2 (13%)
Flushing 0 2 (13%)
General Any event 2 (14%) 3 (20%)
Fatigue 1 (7%) 1 (7%)
Flu-like illness 0 1 (7%)
Asthenia 1 (7%) 0
Malaise 0 1(%)
Infections Any event 3 (21%) 1 (7%)
Nasopharyngitis 3 (21%) 0
Upper respiratory 
tract infection
0 1 (7%)
Renal and urinary 
disorders
Any event 1 (7%) 0
Dysuria 1 (7%) 0
Any event - 11 (79%) 14 (93%)
Injury, poisoning 
and procedural 
complications
Any event 3 (21%) 1 (7%)
Contusion 1 (7%) 0
Muscle strain 1 (7%) 0
Nail injury 0 1 (7%)
Postprocedure 
discomfort
1 (7%) 0
Neurological Any event 1 (7%) 7 (47%)
Headache 1 (7%) 5 (33%)
Paraesthesia 0 1 (7%)
Lethargy 0 1 (7%)
Gastrointestinal Any event 4 (29%) 8 (53%)
Diarrhoea 2 (14%) 4 (27%)
Nausea 1 (7%) 2 (13%)
Upper abdominal 
pain
0 1 (7%)
Dyspepsia 0 2 (13%)
Abdominal 
discomfort
0 1 (7%)
Constipation 1 (7%) 0
Frequent bowel 
motions
0 1 (7%)
Immune system Any event 1 (7%) 0
Seasonal allergy 1 (7%) 0
Vascular Any event 0 2 (13%)
Flushing 0 2 (13%)
Continued
analyser using colorimetric, kinetic and enzymatic ultra-
violet and colour assays (AU2700/AU640 analysers, 
Beckman Coulter), ion-selective electrodes (sodium, 
potassium and chloride assays) and two-point and multi-
ple-point rate assays (Ortho Clinical Vitros 250 analyser). 
Venous blood samples were taken into prelabelled hepa-
rinised sodium tubes for pharmacokinetic assessment of 
plasma SRT2104 concentrations (Simbec Laboratories 
Limited). Serial blood samples were collected on days 
1, 28 and 56 immediately before (0 min) and 15 min, 
30 min, 60 min, 120 min, 180 min, 240 min, 480 min, 720 
min and 1440 min following study medication. Plasma 
was separated by centrifugation of whole blood at 1500 g 
at 4°C for 15 min, and decanted and stored at −80°C until 
analysed.
Plasma concentrations of SRT2104 were measured 
using liquid chromatography with tandem mass spectrom-
etry detection in positive ion mode. High-pressure liquid 
chromatography was performed using Betasil silica–100 
columns using a Phenomenex C18 guard column.27
data analysis and statistics
Plethysmographic data were analysed as described previ-
ously.22 Estimated net release of t-PA and PAI-1 antigen 
and activity was defined as the product of forearm plasma 
flow (based on blood flow and haematocrit) and the 
difference in plasma antigen (or activity) concentrations 
between the two forearms. Fibrinolysis and forearm blood 
flow data were analysed using a linear mixed-model repeat-
ed-measures analysis of covariance. Treatment differ-
ences were investigated in a model adjusting for period, 
treatment by period, vasodilator dose, treatment by vaso-
dilator dose, and vasodilator dose by period using SAS 
for UNIX (V.9.1.3 or higher; SAS Institute). Treatment 
differences in weight, HbA1c, fructosamine and lipid 
variables were analysed using linear mixed-model repeat-
ed-measures analyses of covariance adjusting for baseline, 
period and treatment by period interaction. Values for 
these parameters are expressed as model adjusted (least 
square) means and 95% CIs. Between-day reproducibility 
of forearm venous occlusion plethysmography data were 
assessed using the Bland-Altman method, and coefficient 
of reproducibility was determined for 95% CIs using the 
Student's t-distribution. All other values are expressed 
as mean±SD Statistical significance for treatment differ-
ences was concluded if the two-sided p was <0.05. Interac-
tions and period effects were tested using a significance 
level of 0.10.
Results
The Consolidated Standards of Reporting Trials(CON-
SORT) flow diagram (figure 2) summarises the partic-
ipant screening, exclusion and recruitment process. 
The participants were predominantly middle-aged men 
(58±7.8 years, 13 male), who were obese (body mass 
index 30±3.5 kg/m2) and who had reasonable glycaemic 
control (mean HbA1c 54±8.0 mmol/mol (7.4%±0.80%)).
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System Adverse event
Number of subjects 
with events 
(percentage)
Placebo 
(n=14)
SRT2104 
(n=15)
General Any event 2 (14%) 3 (20%)
Fatigue 1 (7%) 1 (7%)
Flu-like illness 0 1 (7%)
Asthenia 1 (7%) 0
Malaise 0 1(%)
Infections Any event 3 (21%) 1 (7%)
Nasopharyngitis 3 (21%) 0
Upper respiratory 
tract infection
0 1 (7%)
Renal and urinary 
disorders
Any event 1 (7%) 0
Dysuria 1 (7%) 0
Table 1 Continued 
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safety
All of the participants tolerated the study medication. 
Commonly reported side effects occurring in two or more 
volunteers included headache (33%), diarrhoea (27%), 
nausea (13%) and hypoglycaemia (13%) (table 1). 
Apart from one subject describing diarrhoea as ‘severe’, 
the remaining reported adverse events were mild to 
moderate in intensity. All side effects resolved without 
any sequelae. There were no meaningful differences 
in the frequency of treatment-emergent adverse events 
between the active treatment and placebo groups. One 
individual underwent part of the first period of the study 
but was withdrawn because an adverse event criterion was 
met with the concentration of alanine aminotransferase 
being recorded at five times the upper limit of normal. 
After unblinding, this patient was found to have been 
taking placebo at the time of the event.
Pharmacokinetics of sRt2014
After 28 days of active treatment, the mean maximum 
plasma concentration (Cmax) of SRT2104 was 517±355 ng/
mL and 716±359 ng/mL in the first and second treat-
ment periods, respectively. The mean time at which the 
maximum plasma concentration was observed (Tmax) on 
day 28 of dosing was 2.6±1.2 hours and 2.9±1.5 hours in 
the first and second treatment periods, respectively. The 
mean area under the curve was 5300±3473 h.ng/mL in 
the first treatment period and 7312±3708 h.ng/mL in the 
second treatment period. The pharmacokinetics in this 
group was consistent with levels seen in previous studies.27
Cardiovascular effects of sRt2104
Blood pressure and heart rate remained unchanged 
throughout the study. No effects were observed on 
cardiac rhythm or the 12-lead ECG, and specifically the 
corrected and uncorrected QT intervals were unaffected. 
A dose-dependent increase in the infused forearm blood 
flow was observed with all three agonists (acetylcholine, 
bradykinin and sodium nitroprusside) in the presence 
of either SRT2104 or placebo (p<0.0001 for all three 
agonists; figure 3). There were no differences in response 
to acetylcholine (p=0.318) and sodium nitroprusside 
(p=0.083) in the presence of SRT2104 compared with 
placebo. There was a reduction in bradykinin-induced 
vasodilatation with SRT2104 (7.753 vs 9.044, SRT2104 
vs placebo, mean difference=−1.291, (95% CI −2.296 to 
−0.285, p=0.012)) with a trend for a period-by-treatment 
effect (p=0.092).
endogenous fibrinolysis and monocyte and platelet activation
Post hoc analysis showed that dose-dependent incre-
ments were recorded in bradykinin-induced net t-PA 
antigen and activity release (p<0.0001 for both) in the 
infused arm. Estimated net PAI antigen release was 
reduced with SRT2104 compared with placebo (mean 
difference=−38.89 ng/100 mL tissue/min, (95% CI 
−75.47 to –2.305, p=0.038)) with a non-significant 
period effect for the plasma PAI-1 antigen concentra-
tions (p=0.138). There were no differences in net PAI-1 
activity release, or t-PA antigen and activity release 
(p>0.05 respectively). SRT2104 had no effect on markers 
of in vivo platelet or monocyte activation (figure 4).
Metabolic effects
During SRT2104 administration, body weight decreased 
by 0.93 kg (95% CI −1.72 to −0.15, p=0.0236) with a 
treatment-by-period effect (p=0.080). HbA1c rose by 
0.48% (95% CI 0.26% to 0.70%, p=0.004) after 28 days 
of SRT2104, as did plasma fructosamine, which rose by 
33.41 µmol/L (95% CI 20.24 to 46.58 µmol/L, p<0.001).
Post hoc analyses showed that the lipid profile did not 
change (table 2) although trends were noted towards 
lower concentrations of total cholesterol (−0.36 mmol/L, 
95% CI −0.87 to 0.16 mmol/L, p=0.158) and triglycerides 
(−0.22 mmol/L, 95% CI −0.53 to 0.09 mmol/L, p=0.150; 
table 2) with SRT2104. Non-esterified fatty acids rose by 
0.09 mmol/L (95% CI 0.04 to 0.15 mmol/L, p=0.003) 
with a treatment-by-period effect (p=0.0087).
dIsCussIon
The cardiometabolic effects of SRT2104 have not been 
studied previously in people with T2DM. Here we present 
the data in patients with T2DM that are broadly consistent 
with our previously reported observations in otherwise 
healthy cigarette smokers.21 However, we did note some 
important contrasts especially in metabolic parameters.
In otherwise healthy smokers, we have previously 
found no differences in forearm blood flow, platelet 
aggregation and fibrinolysis with SRT2104. Our findings 
in the current T2DM cohort were similar although we 
found modest reductions in bradykinin-induced vaso-
dilatation and net PAI-1 antigen release with SRT2014. 
This finding is unexpected from previous animal 
models.15 17 We did observe some treatment-by-period 
interactions suggesting the potential for an inadequate 
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Figure 2 CONSORT flow diagram of randomisation.
washout period. Moreover, our sample size was modest 
and this could represent a chance finding. An alterna-
tive explanation is that SRT2104 affects a hitherto unde-
scribed pathway which works via bradykinin alone and 
not acetylcholine or sodium nitroprusside. This study 
cannot answer that question presently but generates a 
hypothesis for further examination in the future. Once 
again in contrast to the smokers’ cohort we found a 
statistically significant decrease in PAI-antigen release. 
There was no significant treatment-by-period interac-
tion in this case (p>0.1) which would suggest a poten-
tial fibrinolytic benefit in the treatment arm, although 
this was not confirmed by other measures of t-PA and 
PAI-1 activity, which were unaltered. Taken in aggregate, 
the effect of SRT2104 on cardiovascular measures are 
predominantly neutral although we acknowledge some 
inconsistent changes in isolated measures of vasomotor 
and fibrinolytic function.
Obesity is a major factor in the development of T2DM 
through the promotion of insulin resistance. Weight 
reduction is difficult to achieve in many patients and 
remains a major focus of therapeutic and lifestyle inter-
vention. In the present study a striking reduction in 
weight over a 28-day period was observed that was not 
observed with matched placebo. It is unknown whether 
weight reduction with SRT2104 in overweight patients 
with T2DM would be sustained and have long-term bene-
fits. Whether it could be attributable to appetite suppres-
sion through SIRT1 activation or a consequence of 
enhanced metabolic effects is unclear, but this is a poten-
tially important observation that warrants further inves-
tigation. A treatment-by-period interaction was observed 
with this result as well, so this result should be interpreted 
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Figure 3 Effect of bradykinin (100 pmol/min, 300 pmol/min, 
1000 pmol/min), acetylcholine (5 µg/min, 10 µg/min, 20 µg/
min) and sodium nitroprusside (2 µg/min, 4 µg/min, 8 µg/
min) on absolute forearm blood flow. Blue, placebo; red, 
SRT2104; closed circle and square, infused forearm blood 
flow; open circle and square, non-infused forearm blood flow. 
Data are presented as mean ±95% CI.
Figure 4 Effect of SRT2104 on markers of platelet and 
monocyte activation. Data are presented as mean±SD. 
PMA, platelet-monocyte aggregate; CD11b, CD 11b/
macrophage-1 antigen; sCD40L, soluble CD40 ligand.
Basic and translational research
with caution. If sustained and reproducible, this may 
represent a novel approach to the treatment of obesity.
The loss of weight was associated with an apparent 
short-term deterioration in measures of glycaemic 
control. The elevations of HbA1c and fructosamine 
were puzzling. These observations contradict the find-
ings in models of mice and other higher mammals. 
It is possible that the acute administration of SRT2104 
mimics the early changes of fasting states (decreased 
insulin secretion), and that the subsequent effects of 
decreased insulin sensitivity take longer to develop. This 
may explain the weight loss that was observed and to a 
certain extent the lack of benefit to glycaemic control. 
Supporting this theory, a trend towards decreased peak 
insulin secretion to a glucose challenge was observed in 
a separate study (2-hour postglucose challenge insulin 
concentrations 143 mmol/L vs 117 mmol/L, placebo vs 
SRT2104, p=0.046) where a similar degree of weight loss 
(approximately 1 kg in 28 days) was observed.28 It may 
be that in people with T2DM with established relative or 
absolute insulin deficiency, attenuation of insulin secre-
tion, without a concomitant reduction in insulin resis-
tance, is sufficient to permit a net rise in blood glucose.
Another potential putative mechanism linking SIRT1 
modulation to an acute rise in insulin resistance is the 
inhibition of Peroxisome proliferator-activated receptor 
gamma (PPAR-γ) and the mobilisation of fat from white 
adipose tissue.29 This may be responsible for the modest 
rise in non-esterified fatty acids seen after SRT2104 
administration that could contribute to the change in 
glycaemic control, leading to insulin resistance via intra-
cellular competition with glucose metabolism.30
People with T2DM have complex changes to other 
important glucoregulatory hormones such as glucagon 
and cortisol.31 During acute starvation, important meta-
bolic adaptations occur such as gluconeogenesis and 
an increase in glucocorticoids. These metabolic adapta-
tions maintain the supply of blood glucose to the brain 
during periods of prolonged starvation, but result acutely 
in a constellation of effects similar to insulin resistance. 
However, in people with established T2DM, these protec-
tive glucoregulatory mechanisms described above may 
exacerbate hyperglycaemia in the short term.
Without further study, it is unclear whether long-term 
exposure to SRT2104 will ultimately be metabolically bene-
ficial in patients with T2DM. The promotion of hypergly-
caemia, which is undesirable, conflicts with the beneficial 
effects of weight loss, and it is unknown whether these 
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Table 2 Effect of SRT2104 on serum lipid concentrations
Placebo 
(n=14)
SRT2104 
(n=15) p Value
Total cholesterol (mean (SD)), mmol/L
0.158
  Baseline 4.09 (0.743) 4.24 (0.714)
  Day 28/56 3.91 (0.843) 3.65 (0.710)
  Change from 
baseline
−0.18 (0.410) −0.59 (0.766)
  Mean difference 
(95% CI)
−0.36 (−0.87 to 0.16)
HDL cholesterol, (mean (SD)), mmol/L
  Baseline 1.07 (0.212) 1.08 (0.207)
0.542
  Day 28/56 1.09 (0.210) 1.07 (0.249)
  Change from 
baseline
0.03 (0.080) 0.00 (0.167)
  Mean difference 
(95% CI)
−0.03 (-0.13 to 0.07)
LDL cholesterol,(mean (SD)), mmol/L
  Baseline 2.21 (0.585) 2.29 (0.552)
0.259
  Day 28/56 2.05 (0.692) 1.90 (0.656)
  Change from 
baseline
−0.15 (0.467) −0.39 (0.656)
  Mean difference 
(95% CI)
−0.23 (-0.65 to 0.19)
Triglycerides,(mean (SD)), mmol/L
  Baseline 1.81 (0.800) 1.93 (0.767)
0.150
  Day 28/56 1.67 (0.497) 1.46 (0.445)
  Change from 
baseline
−0.14 (0.568) −0.46 (0.638)
  Mean difference 
(95% CI)
−0.22 (-0.53 to 0.09)
effects are sustained over time. The finding of weight loss 
certainly raises the question as to whether the drug might 
be beneficial in individuals with impaired fasting glucose 
who are treatment-naive, and whether an exposure to the 
drug beyond 28 days would improve glycaemia once the 
downstream effects of increased mitochondrial activity 
and decreased adiposity are further established.
The principal aim of the present study was to establish 
whether SRT2014 could improve a range of markers of 
cardiovascular health in patients with T2DM. Ultimately, 
we did not demonstrate any improvements in vasomotor 
or fibrinolytic vascular function or measures of platelet 
and monocyte activation.
An important question was whether the dose of 
SRT2104 was sufficient to have an effect. As yet, the phar-
macokinetics and pharmacodynamics of SRT2104 are 
not fully elucidated. However, an effect on metabolic 
measures was demonstrated with substantial exposure 
to SRT2104, achieving high plasma SRT2104 concen-
trations in the current study. Even if adequate SIRT1 
activation is assumed, its downstream effects may vary 
in different tissues in different disease states. It may be 
that in advanced states of disease associated with ageing, 
such as T2DM, the beneficial effects are abolished by 
higher caloric consumption, or that the benefits require 
treatment for longer than 28 days to become apparent. 
It might therefore be anticipated that a more prolonged 
exposure is required before any meaningful effect is 
apparent.
In conclusion, SRT2104 appears to be well tolerated 
in patients with T2DM but has no demonstrable bene-
ficial effects on a range of measures of cardiovascular 
health. It is possible that while short-term exposure to 
SRT2104 is effective in mediating weight loss, it appears 
to be associated with an inadequate effect on dimin-
ishing insulin resistance, thereby causing deteriora-
tion in glycaemic control. Further larger-scale studies 
are required to confirm or refute these preliminary 
findings.
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